Mi
Non verificato

MindWalk Holdings Corp.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniSaluteTecnica
13/11/2025
Salute
Tecnica
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Eventi
Fiere
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
1.00
21/10/2025
Software
Scienza
Farmaceutica
Information Technology
Tecnica
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Mercato del lavoro
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
1.00
15/10/2025
Information Technology
Biotecnologia
Tecnica
Salute
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Software
Mercato del lavoro
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
1.00
09/10/2025
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Tecnica
Finanza
MindWalk Announces Share Repurchase Program
1.00
22/09/2025
Industria
Software
Scienza
Farmaceutica
Tecnica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
1.00
15/09/2025
Tecnica
Scienza
HIV, AIDS e malattie autoimmuni
Software
Biotecnologia
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Mercato azionario
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
1.00
10/09/2025
Software
Scienza
Sanità
Reti informatiche
Farmaceutica
Tecnica
Attrezzature medico-sanitarie
HIV, AIDS e malattie autoimmuni
Biotecnologia
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0